Une nouvelle étude ncx6550

Une étude sur ncx6550 vient d'être mise en ligne aujourd'hui et va
paraitre dans le magazine " Microcirculation ". MONSIEUR Ongini en
personne a collaboré pour cette étude prometteuse !!

The cardio-protective properties of NCX-6550, a nitric oxide donating
pravastatin, in the mouse

Clara Di Filippo 1 , Angela Monopoli 2 , Ennio Ongini 2 , Mauro Perretti
3 and Michele D'Amico 1

1 Department of Experimental Medicine, Section of Pharmacology, 2nd
University of Naples, Italy
2 NicOx Research Institute, Via Ariosto, 21, Bresso, Italy
3 The William Harvey Research Institute, Barts and the London School
of Medicine, Queen Mary University of London, Charterhouse Square,
London, EC1M 6BQ, United Kingdom

ABSTRACT

Objective: Determine the cardio-protective properties of a nitric
oxide-releasing pravastatin (NCX-6550), in comparison to pravastatin.

Methods: A mouse model of myocardial infarct was used assessing tissue
damage both at 2 and 24 h post-reperfusion, administering compounds both
prophylactically and therapeutically.

Results: NCX-6550 induced a significant dose-dependent (2.24-22.4
μmol/kg ip) cardioprotection in the 2h reperfusion protocol. In
vehicle-treated mice, infarct size (expressed as fraction of area at
risk; IS/AR) was 41.2±1%, and it was reduced to 22.2±0.9% and 32.6 ±
0.9% following 22.4 and 6.72 μmol/kg NCX-6550 (P<0.05). 22.4
μmol/kg NCX-6550 also increased cardiac levels of the enzyme
heme oxygenase-1. Treatment of mice with pravastatin induced significant
reduction of myocardial injury only at 22.4 μmol/kg (IS/AR
value: 33.7±0.9%). In a 24h reperfusion protocol, NCX-6550 and
pravastatin were tested only at 22.4 μmol/kg i.p., being given
either 1h prior to ischemia (prophylactic protocol) or 1h into
reperfusion (therapeutic protocol). With either treatment scheme,
NCX-6550 produced higher cardioprotection compared to pravastatin, as
reflected also by a reduction in the incidence of lethality as well as
in circulating troponin I and interleukin-1β levels.

Conclusions: These results indicate NCX-6550 as a novel therapeutic
agent with a potential for the treatment of myocardial infarct.

http://www3.interscience.wiley.com/journal/123358379/abstract

C'est une autre molecule que le 6560?

oui c'est un no-pravastatin et ncx6560 : no-astorvastatin , c'est la même catégorie par contre

good news alors, ca + une seconde molecule dans l'ophtalmo ca ferait du bien au pipeline

Bonne nouvelle
Merci

une autre phase 1 pour une molécule finalement assez proche du ncx 6560 ?
mais avec des propriétés "d etonnantes "....puisqu'on évoque le traitement amélioré de l'infarctus du myocarde dans sa phase aigue si j'ai bien compris

a voir si développement futur mais le ncx 6560 semble avoir la priorité ou ,autre hypothese on relance le 6550 suite aux bons résultats 6560 .....

les 2 autres études + anciennes

29 Nitropravastatin, NCX 6550, stimulates therapeutic neovascularization and improves clinical recovery in limb ischemia in STZ-induced diabetic mice
Atherosclerosis Supplements, Volume 7, Issue 3, 2006, Page 191
C. Emanueli, A. Manopoli, M. Melloni, S. Gadau, I. Campesi, E. Ongini, P. Madeddu


Th-P16:408 Nitropravastatin (NCX 6550) is more effective than pravastatin in preventing thrombus formation and intimal thickening in severe hyperlipidemic mice
Atherosclerosis Supplements, Volume 7, Issue 3, 2006, Page 583
S. Momi, G. Gugliemini, A. Monopolu, E. Ongini, P. Gresele

merci

pumpo a écrit:

merci

pumpo juste par curiosité : t'as vu l'ours ?

encore une avancée en cardio qui rend la probabilité d'une offre globale de merck encore plus importante...

OPE? 3 actions Merck pour 2 Nicox...
qui dit mieux?